M&A volume in the pharma and biotech subsectors in 2017 did not match levels seen in previous years but has picked up in 1Q 2018 defying high valuations, market volatility, lack of in-market or late stage assets and global geopolitical uncertainty. This has created an environment where there is little or no room for any variance in value creation models, and necessitates creative post-acquisition strategies in order to maximize target assets’ therapeutic and commercial potential.
This panel will present the results of an internal investigation which examined the capability of shareholder value generation by inorganice growth modalities through a retrospective analysis performed on nearly 300 life sciences transactions completed from 2010 to 2017. Panelists will include pharma and biotech executives as well as investors who will share their first-hand experiences from both the buy and sell sides, providing insights on success factors of shareholder value creation in life sciences.

Ability Level: All

Session ID: 21051